Regenerative Medical Technology Group Inc. Cash Flow Statement
RMTG|9 years of annual SEC 10-K data (FY2017-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 9 fiscal years. All figures from audited SEC 10-K filings.
Regenerative Medical Technology Group Inc. used $706,519 in operating cash flow and negative free cash flow of $1M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -19.75 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$7.8M | -$5.6M | -$9.8M | -$5.5M | -$12.9M | -$5.9M | -$2.5M | -$2.1M | -$377.0K |
| Depreciation & Amortization | $281.1K | $220.6K | $310.1K | $152.7K | $40.9K | $800 | $800 | $200 | - |
| Operating Cash Flow | -$706.5K | $850.7K | -$419.2K | -$1.1M | -$9.9M | -$322.7K | -$362.3K | -$244.6K | -$6.1K |
| Capital Expenditures | $602.6K | $215.4K | $385.6K | $198.4K | - | $100.0K | $100.0K | $4.0K | - |
| Free Cash Flow | -$1.3M | $635.3K | -$804.8K | -$1.3M | - | -$422.7K | -$462.3K | -$248.6K | - |
| FCF Margin | -25.7% | 15.5% | -33.4% | -85.8% | - | -767.5% | -1535.8% | -496.1% | - |